QURE

QURE

USD

uniQure N.V. Ordinary Shares

$30.440-0.370 (-1.201%)

Echtzeitkurs

Healthcare
Biotechnologie
Niederlande

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$30.810

Hoch

$32.490

Tief

$28.500

Volumen

8.90M

Unternehmensfundamentaldaten

Marktkapitalisierung

1.9B

Branche

Biotechnologie

Land

Netherlands

Handelsstatistiken

Durchschnittliches Volumen

3.75M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $5.35Aktuell $30.440Hoch $71.5

Ähnliche Nachrichten

GlobeNewswire

uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (QURE)

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. ("uniQure" or the "Company") (NASDAQ:QURE). The investigation concerns whether the

Mehr anzeigen
Analyst Upgrades

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

Mehr anzeigen
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
Analyst Upgrades

Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $38

Goldman Sachs analyst Salveen Richter maintains uniQure with a Neutral and lowers the price target from $56 to $38.

Mehr anzeigen
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $38
Analyst Upgrades

RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $45

RBC Capital analyst Luca Issi maintains uniQure with a Outperform and lowers the price target from $65 to $45.

Mehr anzeigen
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $45
Analyst Upgrades

William Blair Downgrades uniQure to Market Perform

William Blair analyst Sami Corwin downgrades uniQure from Outperform to Market Perform.

Mehr anzeigen
William Blair Downgrades uniQure to Market Perform
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on uniQure, Lowers Price Target to $70

HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure with a Buy and lowers the price target from $110 to $70.

Analyst Upgrades

Chardan Capital Maintains Buy on uniQure, Lowers Price Target to $53

Chardan Capital analyst Daniil Gataulin maintains uniQure with a Buy and lowers the price target from $76 to $53.

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.